Advances in veterinary oncology offer more treatment options for dogs with cancer. Choosing treatments that balance efficacy with quality of life requires careful welfare-centered decision-making.
Canine cancer treatment welfare centers on ensuring that the burden of treatment does not exceed its benefit in quality-of-life terms. Unlike human oncology where aggressive curative intent is often pursued regardless of side effect burden, veterinary oncology has long integrated quality-of-life as a primary metric. Dogs cannot provide informed consent — welfare assessment must be done by attentive owners and veterinarians working together. Chemotherapy in dogs uses lower doses than human protocols, producing side effects (nausea, fatigue, reduced appetite) in a minority of patients and rarely causing the debilitating toxicity familiar from human treatment. Three-legged dogs after osteosarcoma amputation typically adapt remarkably well and maintain high quality-of-life scores. Palliative care goals — managing pain, maintaining appetite, preserving mobility and normal interactions — are valid treatment endpoints that avoid treatment burden when cure is not realistic. Regular quality-of-life assessment guides escalation or de-escalation of treatment appropriately.